Malignant Hyperthermia: Clinical and Molecular Aspects

Jurkat-Rott, 2005, Muscle channelopathies and critical points in functional and genetic studies, J Clin Invest, 115, 2000, 10.1172/JCI25525 Carpenter, 2009, Genetic variation in RYR1 and malignant hyperthermia phenotypes, Br J Anaesth, 1 Lueck, 2004, Ryanodinopathies: Muscle Disorders Linked to Mutations in Ryanodine Receptors, Basic Appl Myol, 14, 345 Fill, 2002, Ryanodine receptor calcium release channels, Physiol Rev, 82, 893, 10.1152/physrev.00013.2002 Gómez, 2008, Anestesia en la hipertermia maligna, Rev Esp Aneste. siol Reanim, 55, 165, 10.1016/S0034-9356(08)70535-8 Mackrill, 2010, Ryanodine receptor calcium channels and their partners as drug targets, Biochem Pharmacol, 79, 1535, 10.1016/j.bcp.2010.01.014 Balshaw, 2002, Modulation intracellular Calcium-release channels by calmodulin, J Memb Biol, 185, 1, 10.1007/s00232-001-0111-4 Kovacs, 2010, Regulation of ryanodine receptors by sphingosylphosphorylcholine: Involvement of both calmodulin-dependent and -independent mechanisms, Biochem Biophys Res Commun, 401, 281, 10.1016/j.bbrc.2010.09.050 Serysheva, 2008, Subnanometer-resolution electron cryomicroscopy-based domain models for the cytoplasmic region of skeletal muscle RyR channel, Proc Natl Acad Sci, 105, 9610, 10.1073/pnas.0803189105 Meissner, 2004, Molecular regulation of cardiac ryanodine receptor ion channel, Cell Calcium, 35, 621, 10.1016/j.ceca.2004.01.015 Takeshima, 1989, Primary structure and expression from complementary DNA of skeletal muscle ryanodine receptor, Nature, 339, 439, 10.1038/339439a0 Zorzato, 1990, Molecular cloning of cDNA encoding human and rabbit forms of the Ca2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum, J Biol Chem, 265, 2244, 10.1016/S0021-9258(19)39968-5 Du, 2004, Role of the sequence surrounding predicted transmembrane helix M4 in membrane association and function of the Ca (2+) release channel of skeletal muscle sarcoplasmic reticulum (ryanodine receptor isoform 1), J Biol Chem, 279, 37566, 10.1074/jbc.M406637200 Hamilton, 2005, Ryanodine receptors, Cell Calcium, 38, 253, 10.1016/j.ceca.2005.06.037 Marks, 2002, Ryanodine Receptors, FKBP12, and Heart Failure, Front Biosci, 7, 970, 10.2741/marks Samsò, 2005, Internal structure and visualization of transmembrane domains of the RyR1 calcium release channel by cryo-EM, Nature Struct Biol, 12, 539, 10.1038/nsmb938 Fessenden, 2003, Identification of a Key Determinant of Ryanodine Receptor Type 1 Required for Activation by 4-Chloro-m-cresol, J Biol Chem, 278, 28727, 10.1074/jbc.M303821200 Paul-Pletzer, 2002, Identification of a dantroleno- binding sequence on the skeletal muscle ryanodine receptor, J Biol Chem, 277, 34918, 10.1074/jbc.M205487200 Brum, 2003, Differential Effects of Voltage-Dependent Inactivation and Local Anesthetics on Kinetic Phases of Ca21 Release in Frog Skeletal Muscle, Biophys J, 85, 245, 10.1016/S0006-3495(03)74470-1 Copello, 2002, Differential activation by Ca2+ ATP and caffeine of cardiac and skeletal muscle ryanodine receptors after block by Mg2+, J Membr Biol, 187, 51, 10.1007/s00232-001-0150-x Steele, 2007, Defective Mg2+ regulation of RyR1 as a causal factor in malignant hyperthermia, Arch Biochem Biophy, 458, 57, 10.1016/j.abb.2006.03.001 Voss, 2004, Identification of hyperreactive cysteines within ryanodine receptor type 1 by mass spectrometry, J Biol Chem, 279, 34514, 10.1074/jbc.M404290200 Lukyanenko, 2001, Potentiation of Ca(2+) release by cADP-ribose in the heart is mediated by enhanced SR Ca(2+) uptake into the sarcoplasmic reticulum, Circ Res, 89, 614, 10.1161/hh1901.098066 Reiken, 2003, PKA phosphorylation activates the calcium release channel (ryanodine receptor) in skeletal muscle: defective regulation in heart failure, J Cell Biol, 160, 919, 10.1083/jcb.200211012 Hamilton, 2000, Calmodulin and Excitation-Contraction Coupling, News Physiol Sci, 15, 281 Beard, 2002, Calsequestrin is an inhibitor of skeletal muscle ryanodine receptor calcium release channels, Biophys J., 82, 310, 10.1016/S0006-3495(02)75396-4 Bellinger, 2008, Stressed out: the skeletal muscle ryanodine receptor as a target of stress, J Clin Invest, 118, 445, 10.1172/JCI34006 Endo, 2009, Calcium-induced calcium release in skeletal muscle, Physiol Rev, 89, 1153, 10.1152/physrev.00040.2008 Murayama, 2010, Two ryanodine receptor isoforms in nonmammalian vertebrate skeletal muscle: Possible roles in excitationecontraction coupling and other processes, Progress in Biophys. and Mol. Biol, 1 Bers, 2002, Cardiac excitation–contraction coupling, Nature, 415, 198, 10.1038/415198a Islam, 2002, The ryanodine receptor calcium channel of beta-cells: molecular regulation and physiological significance, Diabetes, 51, 1299, 10.2337/diabetes.51.5.1299 Zhou, 2010, Multi-minicore disease and atypical periodic paralysis associated with novel mutations in the skeletal muscle ryanodine receptor (RYR1) gene, Neuromuscular Disorders, 20, 166, 10.1016/j.nmd.2009.12.005 Rosenberg, 2004, Malignant Hiperthermia, Orphanet encyclopedia, 1 Litman, 2005, Malignant Hyperthermia – Update on Susceptibility Testing, Am Med Assoc, 293, 2918, 10.1001/jama.293.23.2918 Amaral JLG, Carvalho RB, Cunha LBP, et al. Hipertermia Maligna. In: Associação Médica Brasileira e Conselho Federal de Medicina (orgs). Projeto Diretrizes. São Paulo: AMB/CFM, 2009. Disponível em: <http://www.projetodiretrizes.org.br/projeto_diretrizes/058.pdf>. Parness, 2009, The myotonias and susceptibility to malignant hyperthermia, Anesth Analg, 109, 1054, 10.1213/ane.0b013e3181a7c8e5 Ali, 2003, Malignant hyperthermia, Best Pract Res Clin Anaesthesiol, 17, 519, 10.1016/j.bpa.2003.09.012 Hopkins, 2000, Malignant hyperthermia: advances in clinical management and diagnosis, Br J Anaesth, 85, 118, 10.1093/bja/85.1.118 Silva, 2000, Susceptibilidade à hipertermia maligna em três pacientes com síndrome maligna por neurolépticos, Arq Neuropsiquiatr, 58, 713, 10.1590/S0004-282X2000000400018 Hernandez, 2009, Scientific advances in the genetic understanding and diagnosis of malignant hyperthermia, J PeriAnesth Nur, 24, 19, 10.1016/j.jopan.2008.12.001 Hors, 1999, Bases genéticas da hipertermia maligna, Rev Bras Anestesiol, 49, 277 Rosenberg, 2002, Testing for malignant hyperthermia, Anesthesiol, 96, 232, 10.1097/00000542-200201000-00036 Krause, 2004, Dantroleno: a review of its pharmacology, therapeutic use, and new developments, Anaesth, 59, 364, 10.1111/j.1365-2044.2004.03658.x Lin, 2004, Dantroleno reduces the threshold and gain for shivering, Anesth Analg, 98, 1318, 10.1213/01.ANE.0000108968.21212.D7 Hadad, 2005, Clinical review: treatment of heat stroke: should dantroleno be considered?, Crit Care, 9, 86, 10.1186/cc2923 Muehlschlegel, 2009, Dantroleno: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit, Neurocrit Care, 10, 103, 10.1007/s12028-008-9133-4 Thorell, 2002, Role of RyRs and IP3 receptors after traumatic injury to spinal cord white matter, J Neurotrauma, 19, 335, 10.1089/089771502753594909 Gronert, 2000, Malignant hyperthermia, 1033